<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39091579</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1923-4163</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of medical cases</Title><ISOAbbreviation>J Med Cases</ISOAbbreviation></Journal><ArticleTitle>Methylphenidate for the Treatment of Post-COVID Cognitive Dysfunction (Brain Fog).</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>200</EndPage><MedlinePgn>195-200</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14740/jmc4254</ELocationID><Abstract><AbstractText>A substantial number of patients develop cognitive dysfunction after contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), significantly contributing to long-coronavirus disease (COVID) morbidity. Despite the urgent and overwhelming clinical need, there are currently no proven interventions to treat post-COVID cognitive dysfunction (PCCD). Psychostimulants like methylphenidate may enhance both noradrenergic and dopaminergic pathways in mesolimbic and pre-frontal areas, thus improving memory and cognition. We present a case series of six patients who were treated at the Johns Hopkins Post-Acute COVID-19 Team (PACT) clinic for PCCD with methylphenidate 5 - 20 mg in the context of routine clinical care and followed for 4 to 8 weeks. Baseline and post-treatment outcomes included subjective cognitive dysfunction and objective performance on a battery devised to measure cognitive dysfunction in long-COVID patients. Three out of the six patients reported subjective improvement with methylphenidate, one patient described it as "notable" and another as "marked" improvement in memory and concentration. We also found significant pre-treatment subjective complaints of cognitive dysfunction; however, formal cognitive assessment scores were not severely impaired. A statistically significant difference in pre and post scores, favoring intervention, was found for the following cognitive assessments: Hopkins verbal learning test (HVLT) immediate recall, HVLT delayed recall and category-cued verbal fluency. The current series demonstrates promising neurocognitive effects of methylphenidate for long-COVID cognitive impairment, particularly in recall and verbal fluency domains.</AbstractText><CopyrightInformation>Copyright 2024, Clark et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Phoebe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Esther S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Ann</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vannorsdall</LastName><ForeName>Tracy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azola</LastName><ForeName>Alba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nickles</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galiatsatos</LastName><ForeName>Panagis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malik</LastName><ForeName>Mansoor</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Med Cases</MedlineTA><NlmUniqueID>101551824</NlmUniqueID><ISSNLinking>1923-4155</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Brain fog</Keyword><Keyword MajorTopicYN="N">Cognitive dysfunction</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword></KeywordList><CoiStatement>None to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>2</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>2</Day><Hour>11</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>2</Day><Hour>4</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39091579</ArticleId><ArticleId IdType="pmc">PMC11287906</ArticleId><ArticleId IdType="doi">10.14740/jmc4254</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Quan M, Wang X, Gong M, Wang Q, Li Y, Jia J. Post-COVID cognitive dysfunction: current status and research recommendations for high risk population. Lancet Reg Health West Pac. 2023;38:100836. doi: 10.1016/j.lanwpc.2023.100836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2023.100836</ArticleId><ArticleId IdType="pmc">PMC10344681</ArticleId><ArticleId IdType="pubmed">37457901</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauria A, Carfi A, Benvenuto F, Bramato G, Ciciarello F, Rocchi S, Rota E. et al. Neuropsychological measures of post-COVID-19 cognitive status. Front Psychol. 2023;14:1136667. doi: 10.3389/fpsyg.2023.1136667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2023.1136667</ArticleId><ArticleId IdType="pmc">PMC10363721</ArticleId><ArticleId IdType="pubmed">37492442</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado-Alonso C, Valles-Salgado M, Delgado-Alvarez A, Yus M, Gomez-Ruiz N, Jorquera M, Polidura C. et al. Cognitive dysfunction associated with COVID-19: a comprehensive neuropsychological study. J Psychiatr Res. 2022;150:40&#x2013;46. doi: 10.1016/j.jpsychires.2022.03.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2022.03.033</ArticleId><ArticleId IdType="pmc">PMC8943429</ArticleId><ArticleId IdType="pubmed">35349797</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings G, Monaghan A, Xue F, Duggan E, Romero-Ortuno R. Comprehensive clinical characterisation of brain fog in adults reporting long COVID symptoms. J Clin Med. 2022;11(12):3440. doi: 10.3390/jcm11123440.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11123440</ArticleId><ArticleId IdType="pmc">PMC9224578</ArticleId><ArticleId IdType="pubmed">35743516</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, Harrison PJ. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. 2022;9(10):815&#x2013;827. doi: 10.1016/S2215-0366(22)00260-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(22)00260-7</ArticleId><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Vertessen K, Luman M, Swanson JM, Bottelier M, Stoffelsen R, Bet P, Wisse A. et al. Methylphenidate dose-response in children with ADHD: evidence from a double-blind, randomized placebo-controlled titration trial. Eur Child Adolesc Psychiatry. 2024;33(2):495&#x2013;504. doi: 10.1007/s00787-023-02176-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00787-023-02176-x</ArticleId><ArticleId IdType="pmc">PMC10869379</ArticleId><ArticleId IdType="pubmed">36862163</ArticleId></ArticleIdList></Reference><Reference><Citation>Drye LT, Scherer RW, Lanctot KL, Rosenberg PB, Herrmann N, Bachman D, Mintzer JE. et al. Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET) Am J Geriatr Psychiatry. 2013;21(6):549&#x2013;559. doi: 10.1016/j.jagp.2012.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2012.12.018</ArticleId><ArticleId IdType="pmc">PMC3402588</ArticleId><ArticleId IdType="pubmed">23567407</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry. 1990;147(1):22&#x2013;30. doi: 10.1176/ajp.147.1.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/ajp.147.1.22</ArticleId><ArticleId IdType="pubmed">2403472</ArticleId></ArticleIdList></Reference><Reference><Citation>Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron. 2012;76(3):470&#x2013;485. doi: 10.1016/j.neuron.2012.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.10.021</ArticleId><ArticleId IdType="pmc">PMC4450094</ArticleId><ArticleId IdType="pubmed">23141060</ArticleId></ArticleIdList></Reference><Reference><Citation>Godfrey J. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. J Psychopharmacol. 2009;23(2):194&#x2013;205. doi: 10.1177/0269881108089809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881108089809</ArticleId><ArticleId IdType="pubmed">18515459</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeschke RR, Sujkowska E, Sowa-Kucma M. Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review. Psychopharmacology (Berl) 2021;238(10):2667&#x2013;2691. doi: 10.1007/s00213-021-05946-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-021-05946-0</ArticleId><ArticleId IdType="pmc">PMC8455398</ArticleId><ArticleId IdType="pubmed">34436651</ArticleId></ArticleIdList></Reference><Reference><Citation>Vannorsdall TD, Brigham E, Fawzy A, Raju S, Gorgone A, Pletnikova A, Lyketsos CG. et al. Cognitive dysfunction, psychiatric distress, and functional decline after COVID-19. J Acad Consult Liaison Psychiatry. 2022;63(2):133&#x2013;143. doi: 10.1016/j.jaclp.2021.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaclp.2021.10.006</ArticleId><ArticleId IdType="pmc">PMC8591857</ArticleId><ArticleId IdType="pubmed">34793996</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt J. The Hopkins verbal learning test: development of a new memory test with six equivalent forms. Clin Neuropsychol. 1991;5:125&#x2013;142.</Citation></Reference><Reference><Citation>Axelrod BN, Lamberty GJ. In: Neuropsychological assessment: a quantified process approach. Poreh AM, editor. Lisse, the Netherlands: Swets &amp; Zeitlinger; 2006. The oral trail making test; pp. 45&#x2013;52.</Citation></Reference><Reference><Citation>Schretlen DJ, Vannorsdall TD. Calibrated ideational fluency assessment (CIFA) professional manual. Odessa, FL: Psychological Assessment Resources; 2010.</Citation></Reference><Reference><Citation>Reiss AB, Greene C, Dayaramani C, Rauchman SH, Stecker MM, De Leon J, Pinkhasov A. Long COVID, the brain, nerves, and cognitive function. Neurol Int. 2023;15(3):821&#x2013;841. doi: 10.3390/neurolint15030052.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/neurolint15030052</ArticleId><ArticleId IdType="pmc">PMC10366776</ArticleId><ArticleId IdType="pubmed">37489358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayat AH, Azimi H, Hassani Moghaddam M, Ebrahimi V, Fathi M, Vakili K, Mahmoudiasl GR. et al. COVID-19 causes neuronal degeneration and reduces neurogenesis in human hippocampus. Apoptosis. 2022;27(11-12):852&#x2013;868. doi: 10.1007/s10495-022-01754-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-022-01754-9</ArticleId><ArticleId IdType="pmc">PMC9310365</ArticleId><ArticleId IdType="pubmed">35876935</ArticleId></ArticleIdList></Reference><Reference><Citation>Saikarthik J, Saraswathi I, Alarifi A, Al-Atram AA, Mickeymaray S, Paramasivam A, Shaikh S. et al. Role of neuroinflammation mediated potential alterations in adult neurogenesis as a factor for neuropsychiatric symptoms in post-acute COVID-19 syndrome - a narrative review. PeerJ. 2022;10:e14227. doi: 10.7717/peerj.14227.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.14227</ArticleId><ArticleId IdType="pmc">PMC9639419</ArticleId><ArticleId IdType="pubmed">36353605</ArticleId></ArticleIdList></Reference><Reference><Citation>Benito-Leon J, Lapena J, Garcia-Vasco L, Cuevas C, Viloria-Porto J, Calvo-Cordoba A, Arrieta-Ortubay E. et al. Exploring cognitive dysfunction in long COVID patients: eye movement abnormalities and frontal-subcortical circuits implications via eye-tracking and machine learning. Am J Med. 2024 doi: 10.1016/j.amjmed.2024.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2024.04.004</ArticleId><ArticleId IdType="pubmed">38583751</ArticleId></ArticleIdList></Reference><Reference><Citation>Taskiran Sag A. COVID-19 associated brain fog and neurocognitive assessment. Cyprus J Med Sci. 2023;8:115&#x2013;120.</Citation></Reference><Reference><Citation>Cristillo V, Pilotto A, Piccinelli SC, Gipponi S, Leonardi M, Bezzi M, Padovani A. Predictors of "brain fog" 1 year after COVID-19 disease. Neurol Sci. 2022;43(10):5795&#x2013;5797. doi: 10.1007/s10072-022-06285-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-022-06285-4</ArticleId><ArticleId IdType="pmc">PMC9361921</ArticleId><ArticleId IdType="pubmed">35930181</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AC, Devason AS, Umana IC, Cox TO, Dohnalova L, Litichevskiy L, Perla J. et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023;186(22):4851&#x2013;4867.e4820. doi: 10.1016/j.cell.2023.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.09.013</ArticleId><ArticleId IdType="pmc">PMC11227373</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Cholevas C, Polyzoidis K, Politis A. Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. Biofactors. 2021;47(2):232&#x2013;241. doi: 10.1002/biof.1726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1726</ArticleId><ArticleId IdType="pmc">PMC8250989</ArticleId><ArticleId IdType="pubmed">33847020</ArticleId></ArticleIdList></Reference><Reference><Citation>Fesharaki-Zadeh A, Lowe N, Arnsten AF. Clinical experience with the &#x3b1;2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in &#x201c;long-COVID19&#x201d;. Neuroimmunol Reports. 2023;3:100154.</Citation></Reference><Reference><Citation>Victor MM, Muller Haas L, Grevet EH, Rohde LA. Successful treatment of post-COVID-19 ADHD-like syndrome: a case report. J Atten Disord. 2023;27(10):1092&#x2013;1098. doi: 10.1177/10870547231168338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10870547231168338</ArticleId><ArticleId IdType="pmc">PMC10102822</ArticleId><ArticleId IdType="pubmed">37052263</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda Y, Sato A, Shichi M, Sato A, Fujii K, Iwasa M, Nagano Y. et al. Real world research on transcranial magnetic stimulation treatment strategies for neuropsychiatric symptoms with long-COVID in Japan. Asian J Psychiatr. 2023;81:103438. doi: 10.1016/j.ajp.2022.103438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajp.2022.103438</ArticleId><ArticleId IdType="pmc">PMC9795803</ArticleId><ArticleId IdType="pubmed">36610206</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabel BA, Zhou W, Huber F, Schmidt F, Sabel K, Gonschorek A, Bilc M. Non-invasive brain microcurrent stimulation therapy of long-COVID-19 reduces vascular dysregulation and improves visual and cognitive impairment. Restor Neurol Neurosci. 2021;39(6):393&#x2013;408. doi: 10.3233/RNN-211249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/RNN-211249</ArticleId><ArticleId IdType="pmc">PMC8764598</ArticleId><ArticleId IdType="pubmed">34924406</ArticleId></ArticleIdList></Reference><Reference><Citation>Eom TH, Kim YH. Clinical practice guidelines for attention-deficit/hyperactivity disorder: recent updates. Clin Exp Pediatr. 2024;67(1):26&#x2013;34. doi: 10.3345/cep.2021.01466.</Citation><ArticleIdList><ArticleId IdType="doi">10.3345/cep.2021.01466</ArticleId><ArticleId IdType="pmc">PMC10764666</ArticleId><ArticleId IdType="pubmed">37321571</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>